Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women
Véronique Demers‐Mathieu, Ciera DaPra, Elena Medo
Abstract
Background: Human milk from coronavirus disease 2019 (COVID-19)-recovered women may be useful as oral antibody therapy to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and provide long-term immunity to neonates and young children. As convalescent plasma is already used as antibody therapy, this study aimed to compare the binding capacity of antibodies specific to the receptor-binding domain (RBD) of SARS-CoV-2 between human milk and serum from COVID-19-recovered women.
Topics & Concepts
MedicineCoronavirusAntibodyImmunologyBreastfeedingCoronavirus disease 2019 (COVID-19)Respiratory systemVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunityDiseaseSevere acute respiratory syndrome coronavirusRespiratory diseaseImmune systemInternal medicinePediatricsInfectious disease (medical specialty)LungCOVID-19 Impact on ReproductionSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy